NanoViricides (NYSE:NNVC) (NYSE: NNVC) is a developmental-stage biotechnology company headquartered in Shelton, Connecticut, specializing in the discovery and development of novel antiviral therapies. Founded in 2005, NanoViricides has pioneered a unique nanomedicine platform designed to target and inactivate a broad spectrum of clinically relevant viruses. The company’s proprietary technology employs nanomicelles—self-assembling polymeric structures—that are engineered to bind specifically to viral surface proteins, neutralizing the virus and preventing infection of healthy cells.
The company’s pipeline encompasses candidate therapeutics for several high-priority viral threats, including influenza, dengue fever, HIV, herpes simplex virus and various coronaviruses. Each nanomicelle is tailored with viral ligand mimics that grant it high specificity for a target virus, while its polymeric nature confers favorable pharmacokinetic properties. Preclinical in vitro and in vivo studies have demonstrated potent antiviral activity, and NanoViricides continues to advance select candidates toward investigational new drug (IND) enabling studies.
NanoViricides operates research facilities in Connecticut and collaborates with academic and contract research organizations in North America, Europe and Asia. The company has forged partnerships to scale up manufacturing and to conduct clinical trials in multiple jurisdictions. By leveraging a modular nanomedicine design, NanoViricides aims to accelerate the timeline from discovery to clinic and address emerging viral threats on a global scale. Its approach also offers the potential for combination therapies, wherein nanomicelles may be co-administered with conventional antivirals to enhance therapeutic efficacy.
Leadership at NanoViricides is headed by Chairman and Chief Executive Officer Anil R. Diwan, Ph.D., a virologist and biotechnologist who co-founded the company. Under Dr. Diwan’s guidance, the executive team has expanded to include experienced professionals in pharmaceutical development, regulatory affairs and business development. This multidisciplinary leadership continues to position NanoViricides as an innovator in the antiviral space, pursuing strategic collaborations and funding pathways to bring its nanomedicine candidates into clinical evaluation.
